Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Many medication and administration statements match the provided label excerpts (indication, duration, frequency, and key application coverage). However, several formulation/vehicle and mechanism details are not supported by the provided label text, and “fungal cell death” and “compromises integrity” are not explicitly stated in the supplied microbiology/pharmacology excerpts.
Category Scores
Accurate Statements
Jublia (efinaconazole) topical solution is a prescription medication used to treat onychomycosis, a fungal infection of the toenail.
Section 1 Indications and Usage: indicated for topical treatment of onychomycosis of the toenail(s due to Trichophyton rubrum and Trichophyton mentagrophytes).
The active ingredient in Jublia is efinaconazole 10%.
Drug description: JUBLIA (efinaconazole) topical solution, 10% (as reflected in provided label excerpts heading/content).
Efinaconazole is an azole antifungal agent.
Section 12.4 Microbiology: “Efinaconazole is an azole antifungal.”
Efinaconazole inhibits fungal lanosterol 14α-demethylase involved in the biosynthesis of ergosterol, a constituent of fungal cell membranes.
Section 12.4 Microbiology: “Efinaconazole inhibits fungal lanosterol 14α-demethylase involved in the biosynthesis of ergosterol, a constituent of fungal cell membranes.”
Jublia is applied once daily to the affected toenail(s) for 48 weeks.
Section 2 Dosage and Administration: “Apply JUBLIA to affected toenails once daily for 48 weeks...”
Jublia is for topical use only (not oral, ophthalmic, or intravaginal).
Section 2 Dosage and Administration: “JUBLIA is for topical use only and not for oral, ophthalmic, or intravaginal use.” (Note: present in label excerpt; not stated in the provided AI claims list exactly, but included in the audit item set as a safety-relevant administration instruction—assessed only for alignment with label excerpt text where applicable.)
Jublia should be applied to the entire nail plate, including the cuticle.
Section 2: requires complete coverage of “toenail, the toenail folds, toenail bed, hyponychium, and the undersurface of the toenail plate.” (Cuticle is not explicitly named in the provided excerpt, but “hyponychium” and “complete coverage” correspond closely to the intended full-structure coverage.)
Jublia should be applied under the nail tip if possible.
Section 2: “ensure… undersurface of the toenail plate” (supports application to the underside/nail plate area, though not phrased as “under the nail tip” in the excerpt).
Unsupported Statements
Efinaconazole works by inhibiting the enzyme lanosterol 14α-demethylase.
While lanosterol 14α-demethylase inhibition is supported (Section 12.4), the AI’s additional linked mechanistic chain below (necessity of ergosterol synthesis and membrane-compromise leading directly to death) is not explicitly stated in the provided excerpts; therefore this combined claim was treated as partially unsupported beyond the explicit inhibitor statement.
Lanosterol 14α-demethylase is essential for the synthesis of ergosterol.
Section 12.4 states the enzyme is involved in ergosterol biosynthesis, but does not explicitly state it is “essential.”
Ergosterol is a vital component of fungal cell membranes.
Section 12.4 calls ergosterol “a constituent” of fungal cell membranes, not “vital.”
By disrupting ergosterol synthesis, efinaconazole compromises the integrity of the fungal cell membrane.
Section 12.4 does not explicitly state membrane integrity compromise as a result of ergosterol synthesis disruption.
Compromising fungal cell membrane integrity leads to fungal cell death.
Not explicitly stated in the provided label excerpts (Section 12.4).
Jublia contains alcohol (SD-40B) at 39.5%.
No formulation/ingredient concentration details (including SD-40B 39.5%) are provided in the supplied label excerpts.
Jublia contains butylene glycol.
No formulation ingredient list is provided in the supplied label excerpts.
Jublia contains hydroxypropyl cellulose.
No formulation ingredient list is provided in the supplied label excerpts.
Jublia contains laureth-23.
No formulation ingredient list is provided in the supplied label excerpts.
Jublia contains propylene glycol.
No formulation ingredient list is provided in the supplied label excerpts.
Jublia contains water.
No formulation ingredient list is provided in the supplied label excerpts.
Nails treated with Jublia should be allowed to dry completely before covering them.
The provided label excerpt includes application coverage and topical-use restrictions, but does not include instructions about drying time before covering.
Contradictions
Important Omissions
Label-supported indication includes restriction to onychomycosis due to Trichophyton rubrum and Trichophyton mentagrophytes.
Importance:
Moderate
Label requires complete coverage of toenail folds, toenail bed, hyponychium, and undersurface of the toenail plate (AI partially paraphrases but does not enumerate all label-specified sites).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported vehicle/formulation concentration claims are unlikely to directly change clinical risk in the absence of patient-specific guidance, but an unsupported application/drying instruction (“dry completely before covering them”) could lead to inaccurate use. Mechanism embellishments (membrane integrity/cell death) are non-label and could mislead; they do not by themselves change dosing safety. Missing label specificity about causative organisms is material to accurate indication framing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several statements are not supported by the supplied label excerpts, especially formulation composition and certain mechanistic and administration details (e.g., drying before covering).
Suggested Improvement
Limit mechanism statements to the label-supported description (azole; inhibits lanosterol 14α-demethylase involved in ergosterol biosynthesis). Remove or qualify unsupported formulation ingredient/concentration claims, and align administration instructions to the label’s specified coverage locations; avoid adding drying/covering guidance not present in the provided excerpts. Include the label’s organism limitation (T. rubrum and T. mentagrophytes) when restating the indication.